Enalapril reduced the risk for new-onset diabetes in left ventricular dysfunction: COMMENTARY

Gerstein, Hertzel
November 2003
ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p68
Academic Journal
Dysglycemic states, including diabetes, impaired glucose tolerance, and lesser degrees of hyperglycemia, are risk factors for subsequent cardiovascular (CV) events. Moreover, non-diabetic patients at high risk for future CV events are likely to be dysglycemic and have a high risk for future diabetes. Such patients had a rate of new-onset diabetes of 1.2% per year. Once diabetes develops, patients are at high risk for retinopathy, neuropathy, renal disease and other complications. Thus, strategies to prevent diabetes in high-risk patients are clearly indicated. Recent clinical trials have shown that diabetes can be prevented or delayed with lifestyle changes, metformin, or acarbose. These trials studied patients with impaired glucose tolerance who had few other risk factors for CV events. Angiotensin-converting enzyme inhibitors may also prevent diabetes.


Related Articles

  • Enalapril reduced the risk for new-onset diabetes in left ventricular dysfunction.  // ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p68 

    This article discusses whether the angiotensin-converting enzyme inhibitor enalapril reduces the risk for new-onset diabetes mellitus more than placebo in non-diabetic patients with left ventricular dysfunction. 291 non-diabetic patients with fasting plasma glucose level less than 7.0 mmol/L...

  • ERRATA.  // Diabetes;Apr2010, Vol. 59 Issue 4, p1113 

    Two corrections to the articles "Reduction of the Accumulation of Advanced Glycation End Products by ACE Inhibition in Experimental Diabetic Nephropathy" and "Human Recombinant ACE2 Reduces the Progression of Diabetic Nephropathy" published in the periodical "Diabetes" are presented.

  • Less Is More. Stanton, Robert C. // Diabetes Health;Oct2005, Vol. 14 Issue 10, p20 

    Provides information on standard and treatment for type 1 and type 2 diabetes. Standard level of blood glucose released by the American Association of Clinical Endocrinologists; Mechanism of action of angiotensin-converting enzyme and angiotensin receptor blockers in diabetics.

  • Angiotensin-Converting—Enzyme Inhibitors for Impaired Glucose Tolerance – Is There Still Hope? Ingelfinger, Julie R.; Solomon, Caren G. // New England Journal of Medicine;10/12/2006, Vol. 355 Issue 15, p1608 

    The author talks about the use of angiotensin-converting enzyme (ACE) inhibitors to prevent or delay the onset of impaired glucose intolerance or diabetes. According to the author, diet and exercise also reduce the risk to develop diabetes. According to the author, several randomized control...

  • Increased tubular organic ion clearance following chronic ACE inhibition in patients with type 1 diabetes. Thomas, Merlin C.; Jerums, George; Tsalamandris, Con; MacIsaac, Richard; Panagiotopoulos, Sianna; Cooper, Mark E. // Kidney International;Jun2005, Vol. 67 Issue 6, p2494 

    Increased tubular organic ion clearance following chronic ACE inhibition in patients with type 1 diabetes.Background.The tubular excretion of creatinine significantly contributes to its clearance. Administration of an angtiotensin-converting enzyme (ACE) inhibitor is associated with increased...

  • ACE in the hole. Luft, Friedrich // Journal of Molecular Medicine;Aug2014, Vol. 92 Issue 8, p793 

    An introduction to the journal is presented in which the author discusses articles about angiotensin-converting enzyme-2 (ACE2), an exopeptidase.

  • Diabetic Kidney Disease: Act Now or Pay Later. Atkins, Robert C.; Zimmet, Paul // Archives of Iranian Medicine (AIM);Jan2010, Vol. 13 Issue 1, p77 

    The article provides information and therapeutics of diabetic kidney disease in the U.S. It states that diabetes is a major cause of end kidney failure throughout the world in both developed and emerging nations. It infers that the disease could be treated using an angiotensin converting enzyme...

  • Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition. Wihler, C.; Schäfer, S.; Schmid, K.; Deemer, E. K.; Münch, G.; Bleich, M.; Busch, A. E.; Dingermann, T.; Somoza, V.; Baynes, J. W.; Huber, J. // Diabetologia;Aug2005, Vol. 48 Issue 8, p1645 

    Aims/hypothesis: Renal accumulation of AGEs may contribute to the progression of diabetic nephropathy. We evaluated the effect of ramipril (a pure ACE inhibitor) and AVE7688 (a dual inhibitor of ACE and neutral endopeptidase) on renal accumulation of the advanced glycation end-product (AGE)...

  • ACE inhibitors reduce all-cause mortality in diabetic nephropathy; data unclear for AIIRAs.  // Formulary;Mar2005, Vol. 40 Issue 3, p91 

    This article reports that a meta-analysis demonstrates that angiotensin converting enzyme (ACE) inhibitors provide a survival benefit in patients with diabetic nephropathy, whereas no such evidence exists for angiotensin II receptor antagonists (AIIAs). Both classes of drugs prevent progression...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics